Lv1
10 积分 2026-03-09 加入
Machine Learning Using Clinical and Cardiac MRI Features to Predict Long-term Outcomes in Acute STEMI
2天前
已完结
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
1个月前
已完结
Evolocumab Achieves Low LDL Cholesterol Without Long-Term Cognitive Risks
1个月前
已完结
Abstract 4139206: Design of Heart-2: a phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol
2个月前
已关闭
VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients
2个月前
已完结
From physiopathology to treatment of Familial Hypercholesterolemia: existing and emerging pharmacotherapies
2个月前
已完结
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
2个月前
已完结
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
2个月前
已完结
Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review
2个月前
已完结
皖公网安备34019202002308
